Two Sigma Advisers
KALV

Two Sigma Advisers’s KalVista Pharmaceuticals KALV Stock Holding History

Two Sigma Advisers’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-22,822
Closed -$193K – 2485
2024
Q4 		$193K Sell
22,822
-15,500
-40% -$161K ﹤0.01% 2132
2024
Q3 		$444K Sell
38,322
-24,800
-39% -$312K ﹤0.01% 1755
2024
Q2 		$744K Sell
63,122
-83,200
-57% -$971K ﹤0.01% 1705
2024
Q1 		$1.74M Sell
146,322
-56,200
-28% -$749K ﹤0.01% 1295
2023
Q4 		$2.48M Buy
202,522
+28,200
+16% +$257K 0.01% 1168
2023
Q3 		$1.68M Buy
174,322
+41,200
+31% +$421K ﹤0.01% 1298
2023
Q2 		$1.2M Buy
133,122
+33,500
+34% +$309K ﹤0.01% 1467
2023
Q1 		$783K Sell
99,622
-12,500
-11% -$93.3K ﹤0.01% 1755
2022
Q4 		$758K Sell
112,122
-2,500
-2% -$13.4K ﹤0.01% 1702
2022
Q3 		$1.66M Sell
114,622
-9,000
-7% -$126K ﹤0.01% 1262
2022
Q2 		$1.22M Buy
123,622
+67,900
+122% +$749K ﹤0.01% 1486
2022
Q1 		$821K Sell
55,722
-59,400
-52% -$853K ﹤0.01% 1748
2021
Q4 		$1.52M Sell
115,122
-5,300
-4% -$84.4K ﹤0.01% 1321
2021
Q3 		$2.1M Buy
120,422
+101,900
+550% +$2.07M 0.01% 1223
2021
Q2 		$444K Buy
18,522
+9,000
+95% +$235K ﹤0.01% 1990
2021
Q1 		$245K Buy
+9,522
New +$250K ﹤0.01% 2293
2019
Q3 		– Sell
-10,222
Closed -$226K – 2312
2019
Q2 		$226K Buy
+10,222
New +$240K ﹤0.01% 2099

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Advisers's KALV Position: Q1 2025 in Review

Two Sigma Advisers sold out of KalVista Pharmaceuticals (KALV) in Q1 2025, closing a stake of 22,822 shares — an estimated $193K sold.

Two Sigma Advisers first reported a position in KALV in Q2 2019 and held it in 17 quarters. The position peaked at $2.48M in Q4 2023. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2025.

  • Two Sigma Advisers reported no remaining KalVista Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 22,822 KalVista Pharmaceuticals shares in Q1 2025, an estimated $193K.
  • Two Sigma Advisers first reported a position in KalVista Pharmaceuticals in Q2 2019 and held it in 17 quarters.
  • Two Sigma Advisers's KalVista Pharmaceuticals position peaked at $2.48M in Q4 2023.
  • 128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.